High doses of fluphenazine enanthate in schizophrenia. A controlled study.

Abstract

The results from this controlled study of 12 schizophrenics refractory to ordinary doses of neuroleptics indicate that treatment with fluphenazine enanthate in higher doses than normal (10--20 times higher) might give reduction in psychopathology beyond what can be obtained with normal doses. In four patients the symptom reduction on high doses was pronounced. Moreover, we found that the high fluphenazine plasma levels demonstrated did not increase extrapyramidal and general side effects. The results presented also speak in favour of certain "non-responding" patients needing a higher plasma level of a neuroleptic drug than the average patient.

• Authors: S J Dencker, R Johansson, L Lundin, U Malm
• Journal: Acta psychiatrica Scandinavica (Acta Psychiatr Scand) Vol. 57 Issue 5 Pg. 405-14 (May 1978) ISSN: 0001-690X [Print] United States
• PMID: 354329 (Publication Type: Case Reports, Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Placebos
• Fluphenazine

Topics

• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Drug Evaluation
• Electrocardiography
• Extrapyramidal Tracts (drug effects)
• Female
• Fluphenazine (administration & dosage, blood, therapeutic use)
• Humans
• Male
• Placebos
• Psychiatric Status Rating Scales
• Schizophrenia (drug therapy)